Thinly traded micro cap Cytosorbents (NASDAQ:CTSO) is up 23% premarket on modestly higher volume in reaction to its announcement that its blood purification device CytoSorb is
now approved in the EU for the removal of anti-platelet agent
ticagrelor (AstraZeneca’s Brilinta, Brilique) during surgery requiring
cardiopulmonary bypass.
CytoSorb accounts for virtually all of the company’s revenues (~$5.6M in Q3 2019).
https://seekingalpha.com/news/3535664-cytosorbents-up-23-premarket-on-expanded-use-of-cytosorb-in-europe
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.